Menu
Search
|

Menu

Close
X

Iovance Biotherapeutics Inc IOVA.OQ (NASDAQ Stock Exchange Global Market)

8.85 USD
-0.04 (-0.45%)
As of 5:41 PM GMT
chart
Previous Close 8.89
Open 8.73
Volume 155,822
3m Avg Volume 390,543
Today’s High 9.17
Today’s Low 8.63
52 Week High 19.80
52 Week Low 7.85
Shares Outstanding (mil) 70.37
Market Capitalization (mil) 552.43
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.010
FY17
-1.411
FY16
-1.774
FY15
-0.620
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
3.81
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-49.36
15.05
Return on Equity (TTM)
vs sector
-80.46
16.62

EXECUTIVE LEADERSHIP

Iain Dukes
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Maria Fardis
President, Chief Executive Officer, Director, Since 2016
Salary: $500,000.00
Bonus: --
Timothy Morris
Chief Financial Officer, Secretary, Since 2017
Salary: $172,212.00
Bonus: --
Frederick Vogt
General Counsel, Since 2017
Salary: $326,355.00
Bonus: --
Sanford Hillsberg
Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

999 Skyway Rd Ste 150
SAN CARLOS   CA   94070-2724

Phone: +1650.2607120

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

SPONSORED STORIES